Coronavirus: Commission reaches first agreement on a potential vaccine
The European Commission recently (14 August 2020) reached a first agreement with the pharmaceutical company AstraZeneca to purchase a potential vaccine against COVID-19 as well as to donate to lower and middle income countries or re-direct to other European countries. This is following the positive steps regarding the conclusion of exploratory talks with Sanofi-GSK announced on 31 July and with Johnson & Johnson on 13 August. Once the vaccine has proven to be safe and effective against COVID-19, the Commission now has agreed the basis for a contractual framework for the purchase of 300 million doses of the AstraZeneca vaccine, with an option to purchase 100 million more, on behalf of EU Member States. The Commission continues discussing similar agreements with other vaccine manufacturers.
Ursula von der Leyen, President of the European Commission, recently said:
“The European Commission's intense negotiations continue to achieve results. Today's agreement is the first cornerstone in implementing the European Commission's Vaccines Strategy. This strategy will enable us to provide future vaccines to Europeans, as well as our partners elsewhere in the world.”
Stella Kyriakides, Commissioner for Health and Food Safety, recently said:
“Today, after weeks of negotiations, we have the first EU advance purchase agreement for a vaccine candidate. I would like to thank AstraZeneca for its constructive engagement on this important agreement for our citizens. We will continue to work tirelessly to bring more candidates into a broad EU vaccines portfolio. A safe and effective vaccine remains the surest exit strategy to protect our citizens and the rest of the world from the coronavirus.”
The agreement approved recently will be financed with the Emergency Support Instrument, which has funds dedicated to the creation of a portfolio of potential vaccines with different profiles and produced by different companies.
AstraZeneca's vaccine candidate is already in large-scale Phase II/III Clinical Trials after promising results in Phase I/II concerning safety and immunogenicity.
The decision to support the vaccine proposed by AstraZeneca is based on a sound scientific approach and the technology used (a non-replicative recombinant chimpanzee adenovirus-based vaccine ChAdOx1), speed at delivery at scale, cost, risk sharing, liability and the production capacity able to supply the whole of the EU, among others.
The regulatory processes will be flexible but remain robust. Together with the Member States and the European Medicines Agency, the Commission will use existing flexibilities in the EU's regulatory framework to accelerate the authorisation and availability of successful vaccines against COVID-19. This includes an accelerated procedure for authorisation and flexibility in relation to labelling and packaging.
Latest News from
Updating the 2020 Industrial Strategy: towards a stronger Single Market for Europe's recovery06/05/2021 16:33:00
The Commission yesterday updated the EU Industrial Strategy to ensure that its industrial ambition takes full account of the new circumstances following the COVID-19 crisis and helps to drive the transformation to a more sustainable, digital, resilient and globally competitive economy.
Commission proposes new Regulation to address distortions caused by foreign subsidies in the Single Market *06/05/2021 15:25:00
The European Commission yesterday proposed a new instrument to address potential distortive effects of foreign subsidies in the Single Market.
European climate law: Council and Parliament reach provisional agreement06/05/2021 14:42:00
The Council's and the European Parliament's negotiators reached a provisional political agreement setting into law the objective of a climate-neutral EU by 2050, and a collective, net greenhouse gas emissions reduction target (emissions after deduction of removals) of at least 55% by 2030 compared to 1990.
President von der Leyen addresses the High Level Scientific Panel for the Global Health Summit06/05/2021 13:25:00
President von der Leyen yesterday addressed the High Level Scientific Panel for the Global Health Summit.
Speech by President von der Leyen at the State of the Union conference of the European University Institute06/05/2021 12:33:00
Speech given yesterday by President von der Leyen at the State of the Union conference of the European University Institute.
Recovery and Resilience Facility: Poland submits official recovery and resilience plan05/05/2021 09:25:00
The Commission has received an official recovery and resilience plan from Poland. This plan sets out the reforms and public investment projects that Poland plans to implement with the support of the Recovery and Resilience Facility (RRF).
Coronavirus: Commission proposes to ease restrictions on non-essential travel to the EU while addressing variants through new ‘emergency brake' mechanism04/05/2021 15:25:00
The Commission yesterday proposed that Member States ease the current restrictions on non-essential travel into the EU to take into account the progress of vaccination campaigns and developments in the epidemiological situation worldwide.
Recovery and Resilience Facility: Belgium, Italy, Austria, and Slovenia submit official recovery and resilience plans04/05/2021 13:25:00
The Commission has received official recovery and resilience plans from Belgium, Italy, Austria, and Slovenia.
European Health Union: Commission publishes open public consultation on the European Health Data Space04/05/2021 12:33:00
The Commission yesterday published an open public consultation on the European Health Data Space (EHDS) – an important building block of the European Health Union.